Literature DB >> 7539734

[The experimental study of anti-human AFP variant McAb in radioimmuno-detection and radioimmuno-therapy of human hepatocellular carcinoma model in nude mice].

Y Liu1, M C Wu, G X Qian.   

Abstract

Anti-human AFP variant monoclonal antibody (AFP-R-LCA McAb) was labeled by 131I and injected intraperiton ealy. The 131I-AFP-R-LCA McAb was gathered in tumor of nude mice bearing human hepatocellular carcinoma (HCC). The tumor/liver radioactivity redio was 5.2, but normal mice IgG labeled by 131I-(131-mIgG) or free 131I was not gathered in tumor and distributed everywhere in average. The group of 131I-AFP-R-LCA McAb was positively visualized by gamma camea. The test showed that 131I-AFP-R-LCA McAb cured the nude mice bearing HCC. The tumor inhibition rate in 131I-AFP-R-LCA McAb group at the 4th week after treatment was significantly higher than those of the other groups (85%, 45%, 20%, 7% respectively, P < 0.05). The result showed that the AFP-R-LCA McAb have strong affinity and special combination to HCC cells and it can be recognized as a carrier for radioimmunodetection and radioimmunotherapy.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7539734

Source DB:  PubMed          Journal:  Zhonghua Wai Ke Za Zhi        ISSN: 0529-5815


  2 in total

1.  Hepatoma-Targeted Radionuclide Immune Albumin Nanospheres: (131)I-antiAFPMcAb-GCV-BSA-NPs.

Authors:  Mei Lin; Junxing Huang; Dongsheng Zhang; Xingmao Jiang; Jia Zhang; Hong Yu; Yanhong Xiao; Yujuan Shi; Ting Guo
Journal:  Anal Cell Pathol (Amst)       Date:  2016-02-15       Impact factor: 2.916

2.  A combination hepatoma-targeted therapy based on nanotechnology: pHRE-Egr1-HSV-TK/(131)I-antiAFPMcAb-GCV/MFH.

Authors:  Mei Lin; Junxing Huang; Xingmao Jiang; Jia Zhang; Hong Yu; Jun Ye; Dongsheng Zhang
Journal:  Sci Rep       Date:  2016-09-19       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.